Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003;56:1366– 1372.
351.
Phillips GL, Prem KA, Adcock LL, et al. Vaginal recurrence of adenocarcinoma of the endometrium. Gynecol Oncol 1982;13:323– 328.
352.
Greven K, Olds W. Isolated vaginal recurrences of endometrial adenocarcinoma and their management. Cancer 1987;60:419–421.
353.
Curran WJ, Whittington R, Peters AJ, et al. Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys 1988;15:803–808.
354.
Poulsen MG, Roberts SJ. The salvage of recurrent endometrial carcinoma in the vagina and pelvis. Int J Radiat Oncol Biol Phys 1988;15:809–813.
355.
Kuten A, Grigsby PW, Perez CA, et al. Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis. Int J Radiat Oncol Biol Phys 1989;17:29–34.
356.
Sears JD, Greven KM, Hoen HM, et al. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 1994;74:1303–1308.
357.
Wylie J, Irwin C, Pintilie M, et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 2000;77:66–72.
358.
Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216–222.
359.
Piver MS, Barlow JJ, Lurain JR, et al. Medroxyprogesterone acetate (Depo-Provera) versus hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 1980;45:268–272.
360.
Podratz KC, O’Brien PC, Malkasian GD Jr, et al. Effects of pro-gestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66:106–110.
361.
Thigpen T, Blessing J, DiSaia P, et al. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience. In: Baulier EE, Iacobelli S, McGuire WL,eds. Endocrinology of malignancy. Park Ridge, NJ: Parthenon, 1986:446–454.
362.
Thigpen T, Blessing J, Hatch K, et al. A randomized trial of medroxyprogesterone acetate (MPA) 200 mg versus 1000 mg daily in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Proc ASCO 1991;10:185.
363.